Drug Trial Radar · NCT03001869
68Ga-PSMA PET/CT in Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
540
Actual
Start
Jul 1, 2017
Primary completion
Jul 1, 2023
Study completion Jul 1, 2023
Sponsor
- Lead sponsor
- Sir Mortimer B. Davis - Jewish General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 23, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to replicate the safety and efficacy of 68Ga-PSMA PET/CT and as a diagnostic and decision making tool in the management prostate cancer patients.The primary endpoints of the study are the incidence of adverse events (AE) in the study population up to 7 days following the scan, and the sensitivity and specificity of 68Ga-PSMA PET/CT vs CT on a per-patient and per-lesion basis.
Conditions
- Prostate Cancer
Interventions
68Ga-HBED-CC-PSMA PET/CTDrug
68Ga-HBED-CC-PSMA PET/CT Scan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of Ga68-PSMA PET/CT imaging as measured by the incidence of adverse events (AE)Time frame: 7 days
- Efficacy of Ga68-PSMA PET/CT imaging as measured by sensitivity and specificity vs CT on a per patient basis as compared to standard of truthTime frame: 12 months
- Efficacy of Ga68-PSMA PET/CT imaging as measured by sensitivity and specificity vs CT on a per lesion basis as compared to standard of truthTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jewish General Hospital
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.